Physician profile
James Walsh
NPI 1265094551
$3,733.50
in general payments reported to CMS, 2019-2025
21 companies · $936 in 2025
The $936 reported for 2025 was more than what 90% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $194 · 2022: $703 · 2023: $619 · 2024: $1,282 · 2025: $936.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,724 · Entertainment: $113.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,724.39 |
| Entertainment | $112.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $744.93 | 2021-2025 | Cequa |
| Ani Pharmaceuticals, INC. | $741.73 | 2024 | Purified Cortrophin Gel |
| Bausch & Lomb Americas INC. | $509.99 | 2022-2025 | Miebo, Infuse, Xiidra |
| Alcon Vision LLC | $374.12 | 2022-2025 | Eysuvis, Dailies Total1, Precision7 |
| Tarsus Pharmaceuticals, INC. | $185.94 | 2024-2025 | Xdemvy |
| Sight Sciences, INC. | $177.45 | 2021-2023 | Tearcare System |
| Novartis Pharmaceuticals Corporation | $174.67 | 2021-2023 | |
| Harrow Eye, LLC | $131.71 | 2024-2025 | Vevye |
| Optos, INC. | $112.58 | 2024 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Horizon Therapeutics Plc | $111.84 | 2022 | |
| Johnson & Johnson Vision Care, INC. | $75.23 | 2025 | |
| Oyster Point Pharma, INC. | $71.47 | 2023-2025 | Tyrvaya, Ryzumvi |
| Dompe US, INC. | $62.00 | 2025 | Oxervate |
| Visionix USA, INC | $55.56 | 2022 | |
| Johnson & Johnson Surgical Vision, INC. | $52.46 | 2022-2023 | Tecnis Iol |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rayner Intraocular Lenses Limited | $39.51 | 2023 | Rayone Emv, Rayone Aspheric, Omidria |
| Coopervision INC. | $38.80 | 2025 | Myday Contact Lens |
| Rxsight INC | $25.08 | 2025 | Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd), Rxsight Injector Cartridge |
| Aerie Pharmaceuticals, INC. | $18.72 | 2021 | |
| Amgen INC. | $16.03 | 2025 | Tepezza |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $13.68 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Walsh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.